The risk of fetal anomalies as a result of progesterone therapy during pregnancy.
The incidence of congenital anomalies in infants born to 382 women treated with P was noted. Only five anomalies occurred in the infants born to women who had taken P. This study supports the data of Rock et al. by demonstrating a similar low incidence of birth defects in a much larger series of patients who also took a much higher dosage of P. Similarly, because only 1 of 189 patients treated with both P and 17-OHP developed anomalies, the data supports the study by Katz et al., suggesting no increase in anomalies related to 17-OHP therapy.
D019326:17-alpha-Hydroxyprogesterone; D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D000022:Abortion, Spontaneous / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000008:administration & dosage / Q000009:adverse effects; D007231:Infant, Newborn; D007273:Injections, Intramuscular; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011374:Progesterone / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D012306:Risk; D013488:Suppositories; D011795:Surveys and Questionnaires; D014621:Vagina
D006908:Hydroxyprogesterones; D013488:Suppositories; D011374:Progesterone; D019326:17-alpha-Hydroxyprogesterone